Title: Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
Abstract: The Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) was a randomized, single-blind, noninferiority trial to evaluate the relative efficacy and safety of intravitreal injections of ranibizumab and bevacizumab (anti–vascular endothelial growth factor (VEGF) agents) for the treatment of neovascular age-related macular degeneration (AMD). At one year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule: bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively, and bevacizumab administered as needed was equivalent to ranibizumab as needed, with 5.9 and 6.8 letters gained, respectively. Ranibizumab given as needed with monthly evaluation had effects on vision that were equivalent to those of ranibizumab administered monthly. The comparison between bevacizumab as needed and monthly bevacizumab was inconclusive.
Publication Year: 2020
Publication Date: 2020-04-01
Language: en
Type: book-chapter
Indexed In: ['crossref']
Access and Citation
Cited By Count: 1
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot